PMID: 26782727Jan 20, 2016Paper

Aflibercept in the Diabetic Macular Edema Treatment

Ceská a slovenská oftalmologie : casopis Ceské oftalmologické spolecnosti a Slovenské oftalmologické spolecnosti
J Studnička

Abstract

Diabetic retinopathy is together with the diabetic macular edema the most common cause of vision loss in the working population. It is also the most common diabetic microvascular abnormality. Aflibercept is approved for the diabetic macular edema treatment, it is a recombinant fusion protein, binding VEGF A, B, and P1GF. The efficacy and safety of the treatment comparing with the laser treatment were set by VIVID-DME and VISTA-DME studies. The T DRCR.net study protocol confirmed the efficacy of aflibercept, ranibizumab, and bevacizumab in the treatment of diabetic macular edema. The best results in the whole group were obtained if using aflibercept, especially in the group of patients with worse initial visual acuity. In all three studies, the safety of intraviteraly applied aflibercept was proven.

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

The New England Journal of Medicine
John A WellsLee M Jampol
The New England Journal of Medicine
Patricio G Schlottmann
The New England Journal of Medicine
C M Gemmy Cheung, Tien Y Wong
The New England Journal of Medicine
M Hossein Nowroozzadeh
© 2022 Meta ULC. All rights reserved